Fatty liver disease, the most common complication of type 2 diabetes (T2D), affects 1 in 5 Canadians. If not managed or treated, a proportion of patients with fatty liver disease may develop the irreversible phases of liver failure, and hepatocellular carcinoma. A new class of drugs, SGLT2 inhibitors (SGLT2i), has been approved by Health Canada […]
Read More